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Introduction: We aimed to evaluate if prior oral anticoagulation (OAC) and its type
determines a greater risk of symptomatic hemorrhagic transformation in patients with
acute ischemic stroke (AIS) subjected to mechanical thrombectomy.
Materials and Methods: Consecutive patients with AIS included in the prospective
reperfusion registry NORDICTUS, a network of tertiary stroke centers in Northern Spain,
from January 2017 to December 2019 were included. Prior use of oral anticoagulants,
baseline variables, and international normalized ratio (INR) on admission were recorded.
Symptomatic intracranial hemorrhage (sICH) was the primary outcome measure.
Secondary outcome was the relation between INR and sICH, and we evaluated mortality
and functional outcome at 3 months by modified Rankin scale. We compared patients
with and without previous OAC and also considered the type of oral anticoagulants.
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Results: About 1.455 AIS patients were included, of whom 274 (19%) were on OAC,
193 (70%) on vitamin K antagonists (VKA), and 81 (30%) on direct oral anticoagulants
(DOACs). Anticoagulated patients were older and had more comorbidities. Eighty-one
(5.6%) developed sICH, which was more frequent in the VKA group, but not in DOAC
group. OAC with VKA emerged as a predictor of sICH in a multivariate regression model
(OR, 1.89 [95% CI, 1.01–3.51], p = 0.04) and was not related to INR level on admission.
Prior VKA use was not associated with worse outcome in the multivariate regression
model nor with mortality at 3 months.
Conclusions: OAC with VKA, but not with DOACs, was an independent predictor of
sICH after mechanical thrombectomy. This excess risk was associated neither with INR
value by the time thrombectomy was performed, nor with a worse functional outcome
or mortality at 3 months.
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INTRODUCTION
Symptomatic intracranial hemorrhage (sICH) is a life-
threatening complication associated with reperfusion therapies
after acute ischemic stroke (AIS) (1). Treatment with direct
oral anticoagulants (DOACs), or vitamin K antagonists
(VKA) with an international normalized ratio (INR) > 1.7
was a contraindication for the administration of intravenous
thrombolysis due to the increased risk of intracranial bleeding
(2). However, the risk of developing symptomatic hemorrhagic
transformation in anticoagulated patients is not yet fully
established after endovascular treatment (EVT) (3). Patients
taking oral anticoagulation (OAC) were often underrepresented
in pivotal clinical trials of mechanical thrombectomy, accounting
for <5% of the total (4). To date, it has been a matter of
controversy if EVT in AIS with prior anticoagulant treatment
carries a major risk of bleeding. It is essential to select the best
therapeutic approach in this subset of patients, because despite
best medical treatment with anticoagulation 1–3% of patients
will develop strokes annually (5).
In addition, there is little data regarding the possible influence
of the type of anticoagulant (VKA vs. DOACs) and the risk
of sICH after EVT in AIS. Recently, a systematic review and
meta-analysis demonstrated that patients under VKA treatment
had an increased risk of sICH and mortality after mechanical
thrombectomy (1), although another observational study did not
report differences in the rates of sICH between patients under
VKA compared with DOACs (6).
Data are also limited and inconclusive regarding the
relationship between the intensity of anticoagulation and the risk
of sICH after EVT (7, 8). To date, neither INR level above a
certain threshold nor DOAC activity values have been associated
with an increased sICH or poor outcome risk. Thus, clarification
of these scientific questions would satisfy considerable clinical
need, since EVT is the only therapeutic option for anticoagulated
AIS patients with a large vessel occlusion (9).
We aimed to study whether prior OAC, either assessed as a
whole group or focusing on the type of oral anticoagulants used,
was associated with an increased risk of sICH in AIS patients. As
secondary aims, we studied the relationship between INR level at
the time of treatment and sICH risk and the impact of prior OAC
on functional outcome and predictors of mortality in all cohort.
MATERIALS AND METHODS
Study Design and Patient Selection
We performed a retrospective, observational, multicentric study
based on a prospective registry of all consecutive AIS patients
treated with reperfusion therapies in tertiary Stroke Centers in
Spain included in the NORDICTUS Registry between 2017 and
2019. NORDICTUS is a research network in cerebrovascular
diseases that brings together all public hospitals with stroke
units in North-West Spain serving an area of 11.5 million
people. Fourteen tertiary stroke centers participated in the
investigation and the study was approved by their respective
local institutional Clinical Research Ethics Committee. Written
informed consent was obtained from all included patients or their
relatives giving permission to enter their information into our
reperfusion registry and to use of the data for scientific purposes,
in accordance with the Spanish Personal Data Protection law.
Patients treated with mechanical thrombectomy included in
the Nordictus Registry were selected for this study if they
fulfilled the following criteria: (1) patients with disabling focal
neurological deficit and ischemic stroke with demonstrated vessel
occlusion, (2) time from symptom onset to groin puncture
<24 h, including wake up strokes and unknown onset, (3) no
intracranial hemorrhage at baseline cranial tomography (CT);
(4) no extensive early ischemic signs as defined by an Alberta
Stroke Program Early CT Score (ASPECTS) > 5 (10); (5) in
patients with time from symptom onset to EVT>6 h, presence of
a target mismatch profile on CT perfusion (11); and (6) absence
of previous relevant disability evaluated by the modified Rankin
Scale (mRS) (pre-stroke mRS score ≤2). If no contraindication
existed (including INR<1.7 in those under VKA or DOAC in the
prior 48 h), prior treatment with rt-PA was administered before
EVT following regular guidelines.
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Clinical Data and Baseline Variables
All patients included were clinically managed according to our
institutional protocols, which are based on current international
stroke guidelines. Our reperfusion registry includes the following
baseline variables: age, sex, previous functional disability defined
by mRS, information about the presence of arterial hypertension,
diabetes, dyslipidemia, smoking, atrial fibrillation, history of
coronary disease, or stroke prior to admission, previous
treatment with antiplatelets, or anticoagulants and their type
(VKA, DOACs, heparin). Anticoagulation status was recorded
at the time of admission, and urgent INR was obtained in all
patients prior to thrombectomy. Information regarding baseline
clinical stroke severity according to National institute of Health
Stroke Scale (NIHSS) score, location of artery occlusion and
treatment, type of anesthesia during the procedure, and time
intervals were also recorded. Stroke subtypes were categorized
according to the Trial of ORG 10172 in Acute Stroke Treatment
(TOAST) classification (12).
Neuroimaging Protocol
A basal cranial noncontrast CT and CT angiography (CTA) scan
was performed before endovascular treatment. Extent of early
ischemic changes was evaluated by ASPECTS, and the arterial
occlusion site was defined based on the CTA.
Targetmismatchwas established by a core volume of<70 cm3,
a penumbra/core ratio >1.8, and a mismatch volume >15 ml.
Recanalization after EVT was evaluated by the Thrombolysis
in Cerebral Infarction (TICI) scale (13) and considered successful
when TICI 2b-3 was achieved after the procedure.
A follow-up brain CTwas performed after 24 h of treatment or
earlier in case clinical deterioration occurred with the intention to
assess the presence of hemorrhagic transformation. Hemorrhagic
transformation subtypes were categorized according to the
European Cooperative Acute Stroke Study (ECASS-2) definition
as hemorrhagic infarction (HI) types 1 and 2 and parenchymal
hematoma types 1 and 2 (14). In addition, sICH was
defined according to Heidelberg criteria (15) as hemorrhagic
transformation that was associated with significant neurological
worsening, which was defined as an increase of four or more
points in the NIHSS scale (15).
Primary and Secondary Outcome
The primary study outcome was the presence of sICH after
endovascular treatment.
As secondary outcomes, we aimed to evaluate whether the
INR value in patients on VKA at the time of treatment carries a
higher risk of sICH. We also studied predictors of mortality and
poor functional outcome at 3 months after the stroke, which was
defined as a modified Rankin score >2.
Also, we compared outcomes in patients with and without
previous use of OAC and according to the type of oral
anticoagulants (VKA vs. DOACs).
Statistical Analysis
Data from each center were prospectively included in an
anonymized online database of NORDICTUS research groups
and statistical analysis after exporting the data was performed
using SPSS statistics version 24 (Chicago, Illinois, USA).
Baseline quantitative continuous variables were expressed
using their mean, standard deviation (SD) or median
(interquartile range), as appropriate. Categorical variables
were presented as number of cases and their percentage (%).
Normality distribution of the data was assessed by using
Kolmogorov-Smirnov test. Baseline characteristics of the study
groups were compared using the Chi-square test for discrete
variables, t-student test for quantitative variables with a normal
distribution and Mann-Whitney U test for quantitative variables
not following a normal distribution.
Bivariate analyses were performed to detect baseline variables
associated with the occurrence of the primary and secondary
endpoints. A logistic regression analysis was performed to
identify independent predictors of sICH, poor functional
outcome, and mortality. Adjustment was performed for all
variables showing a p < 0.1 on the respective bivariate
analysis. Age, arterial hypertension, dyslipidemia, and atrial
fibrillation were also entered into the model as relevant potential
confounding factors derived from recent literature (6) and from
our bivariate analysis of variables associated with prior OAC.
We performed a subgroup analysis to evaluate the influence of
the type of anticoagulant (VKA vs. DOACs) on the outcomes.
The logistic regression data are presented as adjusted odds
ratio (OR) and respective 95% confidence intervals (CI) and
statistical significance level was defined as a p value < 0.05. OR
for ASPECTS and mRS was expressed as per 1-point increased
in LR model. In the subgroup of VKA-treated patients, we
performed a multivariate analysis to analyze the relationship
between pretreatment INR level and sICH risk implementing
continuous INR.
RESULTS
From January 2017 to December 2019, 1,710 consecutive
patients treated with mechanical thrombectomy were included
in the NORDICTUS stroke registry. From those patients who
underwent EVT, 1,455 fulfilled our inclusion criteria. Reasons for
exclusion of the remaining patients were treatment with heparin
(n= 14), prestroke mRS>2 (n= 172), and unavailable follow-up
data (n= 69).
The distribution of baseline variables of the study group is
shown in Table 1. Six hundred and sixty-four patients (46%)
were women, the mean age of the overall population was 72.42
years (SD: 12.84) and median NIHSS at admission was 16 (10–
20). Two hundred and seventy-four patients (19%) were on oral
anticoagulants, 193 on VKA (70%) and 81 (30%) on DOACs.
Regarding baseline characteristics according to
anticoagulation status (Table 1), patients on OAC (DOACs
and VKA) were older and had significantly higher prevalence of
arterial hypertension, dyslipidemia, previous atrial fibrillation,
ischemic cardiopathy, and previous stroke. VKA patients had
higher punctuations on baseline NIHSS and lower ASPECTS
compared with DOACs and non-OAC patients. Site of occlusion
were not statistically different between both groups, except for
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p Valuea P valueb
Age (year, mean ± SD) 72.4 ± 12.8 71.5 ± 13.2 76.37 ± 9.79 76.66 ± 10.2 <0.001 0.73
Sex [women; n (%)] 664 (46) 525 (45) 38 (48) 101 (52) 0.13 0.50
Hypertension [n (%)] 927 (64) 729 (62) 59 (73) 139 (72) 0.005 0.53
Diabetes mellitus [n (%)] 285 (20) 221 (19) 19 (24) 45 (23) 0.22 1
Dyslipidemia [n (%)] 705 (49) 550 (47) 47 (58) 108 (57) 0.01 0.89
Atrial fibrillation [n (%)] 402 (28) 153 (13) 78 (96) 171 (89) <0.001 0.11
History of coronary disease [n (%)] 197 (14) 140 (12) 17 (21) 40 (21) <0.001 1
Previous stroke [n (%)] 188 (13) 121 (10) 18 (23) 49 (25) <0.001 0.64
Smoking [current or past; n (%)] 463 (33) 398 (35) 19 (24) 46 (24) <0.001 0.90
Prior mRS [0–1; n (%)] 1,282 (88) 1,065 (90) 60 (74) 157 (81) <0.001 0.38
Antiplatelet treatment 343 (24) 323 (27) 5 (6) 15 (8) <0.001 0.59
Acetylsalicylic acid [n (%)] 343 (24) 262 (22) 3 (4) 12 (6) <0.001 0.56
Clopidogrel [n (%)] 277 (19) 33 (3) 2 (3) 2 (1) 0.35 0.58
Double antiplatelet therapy [n (%)] 37 (3) 17 (1) 0 1 (1) 0.32 1
Baseline NIHSS median (IQR) 16 (10–20) 16 (10–20) 15 (9–20) 18 (12–21) 0.027 0.05
Baseline ASPECTS median (IQR) 9 (8–10) 9 (8–10) 10 (8–10) 8 (7–10) 0.13 <0.001
MCA-M1 occlusion [n (%)] 792 (55) 625 (54) 49 (61) 118 (62) 0.09 0.34
Tandem occlusion [n (%)] 250 (17) 230 (20) 6 (7) 14 (7) <0.001 1
TOAST [cardioembolic origin; n (%)] 682 (50) 438 (40) 70 (91) 174 (93) <0.001 0.58
Known time of symptom onset (%) 964 (66) 785 (67) 53 (66) 126 (65) 0.94 1
Time intervals [median (IQR) min]
Onset-to-door time 115 (228–61) 118 (234–61) 97 (54–236) 104 (60–216) 0.15 0.73
Onset-to-arterial puncture 218 (318–161) 225 (320–165) 197 (152–300) 201 (160–312) 0.07 0.30
OAC, oral anticoagulation; DOACs, direct oral anticoagulants; VKA, vitamin K antagonist; NIHSS, National Institute of Health Stroke Scale; TOAST, Trial of Org 10172 in acute stroke
registry; ASPECTS, Alberta Stroke Program Early CT Score; MCA, middle cerebral artery; IQR, interquartile range; mRS, modified Rankin Scale.
ap-values indicate comparisons between overall groups.
bp-values indicate comparisons between DOACs and VKA.
a lower proportion of tandem occlusion in the OAC group.
Prestroke functional status (mRS 0–1) was worse compared with
patients who were not on oral anticoagulants. Also, patients on
OAC tended to have more cardioembolic strokes.
In terms of safety, the proportion of patients with sICH was
similar in patients with and without oral anticoagulants.
As shown in Supplementary Table 1, the proportion of
patients treated with rt-PA differed between two groups. As
expected, prior intravenous thrombolysis was less frequently
given in the OAC group (p = <0.001). Successful and near to
complete recanalization (TICI 2b or 3) was achieved in 86%
patients of the overall sample and was similar in non-OAC vs.
OAC patients.
Main Outcome: Symptomatic Intracerebral
Hemorrhage
Bivariate analysis of baseline variables potentially associated with
sICH is shown in Table 2. Patients who had a sICH were more
often on VKA treatment, had worse prestroke functional status,
and less often had a more proximal large vessel occlusion. Higher
baseline NIHSS, lower ASPECT score, and longer onset to door
and onset to groin puncture times were also associated with a
higher sICH risk on bivariate analysis.
After multivariate analysis, prior VKA treatment (OR, 1.89
[95% CI, 1.01–3.51], p = 0.04), prior mRS (OR, 1.43 [95% CI,
1.03–1.99]), p = 0.03), and basal ASPECTS on admission (OR,
0.72 [95% CI, 0.61–0.84]), p < 0.001) emerged as independent
predictors of sICH (Table 3).
Secondary Outcomes
In the group of patients on VKA, we evaluated the association
between pre-treatment INR and sICH risk using INR as a
continuous variable. The multivariate analysis did not disclose
any significant association between these variables in an
unadjusted (OR, 1.13 [95% CI, 0.52–2.46], p = 0.74) and after
adjusted model (OR, 1.01 [95% CI, 0.42–2.41], p= 0.97).
Patients on oral anticoagulants had lower rates of functional
independence at the third month (50 vs. 43%, p = 0.050).
No significant differences in mortality within 90 days were
observed in patients under oral anticoagulant treatment vs. non-
anticoagulated patients.
Prior VKA treatment was associated with a worse outcome
in bivariate analysis (p = 0.002) but not after multivariate
adjustment (OR, 1.13 [95% CI, 0.76–1.67], p= 0.52) (Table 4).
As shown in Supplementary Table 2, after multivariate
analysis, the predictors of mortality in all cohort were older
age (OR, 1.03 [95% CI, 1.02–1.05], p < 0.001), worse prestroke
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TABLE 2 | Baseline characteristics of whole study sample and bivariate analysis






Age (year, mean ± SD) 72.3 ± 12.9 73.4 ± 11.1 0.78
Sex [women; n (%)] 631 (46) 33 (42) 0.48
Hypertension [n (%)] 874 (64) 53 (65) 0.81
Diabetes mellitus [n (%)] 266 (20) 19 (24) 0.38
Dyslipidemia [n (%)] 668 (49) 37 (46) 0.64
Atrial fibrillation [n (%)] 376 (28) 26 (33) 0.47
History of coronary disease [n (%)] 187 (14) 10 (12) 0.86
Previous Stroke [n (%)] 172 (13) 16 (20) 0.08
Smoking (current or past) [n (%)] 437 (33) 26 (32) 0.49
Prior mRS 0–1 [n (%)] 1218 (89) 64 (79) 0.01
OAC [n (%)] 254 (19) 20 (25) 0.18
Treatment with VKA 174 (13) 19 (24) 0.01
Treatment with DOACs 80 (6) 1 (1.2) 0.08
Antiplatelet [any, n (%)] 329 (24) 14 (17) 0.5
Acetylsalicylic acid [n (%)] 264 (19) 13 (16) 0.56
Clopidogrel [n (%)] 36 (3) 1 (1) 0.7
Double antiplatelet therapy [n (%)] 18 (1) 0 0.61
Baseline NIHSS [median, (IQR)] 16 (10–20) 18 (13–21) 0.02
Baseline ASPECTS [median, (IQR)] 9 (8–10) 8 (9–7) <0.001
MCA-M1 occlusion [n (%)] 755 (56) 37 (46) 0.04
Tandem occlusion [n (%)] 232 (17) 18 (22) 0.22
TOAST [cardioembolic origin; n (%)] 649 (50) 33 (45) 0.81
Known time of symptom onset (%) 912 (66) 52 (64) 0.71
Time intervals [median (IQR) min]






NIHSS, National Institute of Health Stroke Scale; TOAST, Trial of Org 10172 in acute stroke
registry; ASPECTS, Alberta Stroke Program Early CT Score; MCA, middle cerebral artery;
IQR, interquartile range; mRS, modified Rankin Scale; OAC, oral anticoagulation; DOACs,
direct oral anticoagulants; VKA, vitamin K antagonist.
functional status (OR, 1.37 [95% CI, 1.12–1.68], p = 0.002),
higher punctuation on NIHSS on admission (OR, 1.07 [95% CI,
1.05–1.01], p < 0.001), and higher rates of proximal occlusion
(OR, 1.11 [95% CI, 1–1.23], p= 0.044).
Subgroup Analysis in OAC Patients (VKA
vs. DOACs)
We performed a separate multivariate-adjusted logistic
regression model in the group of patients treated with
oral anticoagulants. Prior anticoagulation with VKA was
associated with a significant increase in sICH risk when
compared with DOACs (OR, 8.41 [95% CI, 1.03–68.54]),
p= 0.04).
DISCUSSION
In this observational study based on a prospective multicenter
reperfusion registry, the most important finding was that
TABLE 3 | Logistic regression: predictors of symptomatic intracranial hemorrhage.
OR (IC 95%) p-value
Prior mRS 1.43 (1.03–1.99) 0.03
Baseline NIHSS 1 (0.96–1.05) 0.72
ASPECTS 0.71 (0.61–0.84) <0.001
Treatment with VKA 1.89 (1.01–3.51) 0.04
Treatment with DOACs 0.32 (0.04–2.42) 0.27
Vessel occlusion MCA-M1 0.91 (0.71–1.16) 0.46
Age 1.01 (0.99–1.04) 0.2
Arterial Hypertension 0.89 (0.51–1.55) 0.68
Hypercholesterolemia 0.82 (0.49–1.37) 0.46
Atrial fibrillation 0.79 (0.54–1.17) 0.25
mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; ASPECTS,
Alberta Stroke Program Early CT Score; MCA, middle cerebral artery; VKA, vitamin
K antagonist.
TABLE 4 | Logistic regression model: predictors of poor functional outcome at 3
months of all cohort.
OR (IC 95%) p-value
Age 1.04 (1.02–1.05) <0.001
Sex (women) 1 (0.75–1.32) 0.99
Arterial hypertension 1.20 (0.89–1.60) 0.21
Diabetes mellitus 1.21 (0.86–1.70) 0.26
Prior mRS 1.61 (1.31–1.98) <0.001
Baseline NIHSS 1.09 (1.07–1.11) <0.001
Vessel occlusion MCA-M1 1.06 (0.95–1.17) 0.27
VKA treatment 1.13 (0.76–1.67) 0.52
ASPECTS 0.73 (0.66–0.81) <0.001
Atrial fibrillation 0.92 (0.77–1.10) 0.39
Onset-to-door time 1 (0.99–1) 0.68
mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; MCA,
middle cerebral artery; VKA, vitamin K antagonist; ASPECTS, Alberta Stroke Program
Early CT Score.
prior anticoagulation with VKA emerged as an independent
predictor of sICH in AIS patients undergoing EVT. This excess
bleeding risk associated with VKA contrasts with the lack of
association between the use of DOACs and sICH risk, which
suggests that DOACs have a better safety profile than VKA
in the setting of EVT for AIS. This different safety profile
is another solid reason to prescribe DOACs over VKA to
try to prevent ischemic stroke in patients with non-valvular
atrial fibrillation.
Our main observation is in line with a recent systematic
review and meta-analysis (1), that has reported higher sICH
rates in VKA users but not in patients under DOACs. The
authors of that study described a significant increase in mortality
in patients anticoagulated with VKA, which we did not find
in our series. This excess mortality associated with VKA has
also been found by other studies. Taken together, all these
findings contribute to raise the questions of whether there
is a high-bleeding risk profile among patients treated with
VKA undergoing EVT and if EVT is safe in all circumstances
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for patients anticoagulated with VKA. Future research should
address these issues (1, 16). Use of VKA was associated with
worse functional outcome at 3 months in bivariate analysis
but did not predict functional dependence in the multivariate
regression model, in accordance with a recent study (6). This lack
of association with poor functional outcome could be due to the
role of confounding factors associated with the use of VKA, such
as age, comorbidities, premorbid status, or higher incidence of
atrial fibrillation (17) in patients under VKA treatment compared
with nonanticoagulated patients.
In our study, we did not find an association between pre-
EVT INR level and the risk of sICH among VKA patients.
However, only seven patients had a value of INR >3, so this
precludes any conclusion. On the other hand, our result is in
agreement with previous works showing that increased INR
was not associated with higher sICH risk (6–8, 18). Thus,
pretreatment INR level may not reflect the risk of bleeding after
EVT, and therefore exclusion of EVT candidates based on INR
level, as done with intravenous thrombolysis patients, does not
seem to be justified according to existing evidence. The fact
that these patients had an ischemic stroke under anticoagulation
and subsequently a severe hemorrhagic complication after EVT,
might be related to high instability or fluctuations of the intensity
of anticoagulation under VKA (3). In this setting, it would have
been ideal to evaluate the risk associated with the percentage
of time patients were in range of effective anticoagulation
during the previous months, but this data was not available in
our registry.
In our study, the rates of sICH between oral anticoagulated
patients and those not taking oral anticoagulants was similar,
which is also in agreement with previous reported series (18,
19). Moreover, recanalization rates were also similar in the two
groups. Other series have reported better TICI scores in patients
receiving OAC, raising the prospect that anticoagulation itself
may reduce fibrin formation and facilitate EVT (6) or that
thrombus from cardioembolic origin could be more prone to
be removed (20), but this is unclear (21). According to our
results, we can affirm that EVT is safe and feasible in the context
of previous anticoagulation as previously reported (22). Our
proportion of anticoagulated patients subjected to EVT (19%)
is slightly higher than rates reported in most recently published
data (6); this emphasizes the importance of the occurrence
of stroke in previous anticoagulated patients who will further
require reperfusion therapy (17). Our rate of sICH is 5.6%, which
is also in line with the proportion reported in recent series of
patients with AIS treated with mechanical thrombectomy (1, 6).
Even with this higher risk of sICH in VKA patients, EVT should
be performed if there are no other contraindications. Moreover,
we have to identify a clinical profile that can predict the higher
risk of bleeding, to determine if EVT is safe in all circumstances
for VKA patients.
This study faces some limitations. First, this is a retrospective
analysis from non-randomized, observational data. Second,
the selection of patients for EVT was conducted at the
discretion of each center and this could represent a confounding
factor for the indication of EVT. Third, we could not
estimate DOACs compliance or activity or INR therapeutic
range of VKA patients, which perhaps facilitates the risk
of sICH after EVT, even when IVT was withheld in 91%
of OAC patients in our series. Finally, the small number
of sICH events limited the number of variables entered in
the multivariate regression model. Therefore, the influence of
other nonconsidered potential confounding variables cannot be
entirely ruled out.
CONCLUSIONS
Prior use of VKA, but not of DOACs, was associated with
an increased risk of sICH in patients with AIS subjected
to EVT. However, this was not related to worse outcome
at 3 months. The risk of sICH was not associated with
the intensity of anticoagulation as determined by the
pre-EVT INR level in patients treated with VKA. Prior
anticoagulation with DOACs appears to have a better
safety profile when compared with VKAs in AIS patients
undergoing thrombectomy.
DATA AVAILABILITY STATEMENT
The datasheets are available upon reasonable request to the
corresponding author.
ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by fourteen tertiary stroke centers participated in the
investigation and the study was approved by their respective
local institutional Clinical Research Ethics Committee. The
patients/participants provided their written informed consent to
participate in this study.
AUTHOR CONTRIBUTIONS
MER-A drafted the manuscript and performed statistical
analysis. AC-M partly drafted the manuscript. EL-CM, MC,
JMar, JTG, PR, and EPP critically reviewed the manuscript.
AC-M, BG-V, EL-CM, MCA, MC, MLF, HTM, JMar, JTG,
IBR, PR, ND, SAR, MSC, YBA, MBI, MRG, JTF, NAB,
JMac, PVA, FJV, APB, IA, FM, and AL acquired data. JFA
conceived the study, acquired data, and critically reviewed the
manuscript. All authors contributed to the article and approved
the submitted version.
FUNDING
MER-A was funded by The Instituto de Salud Carlos III
(JR19/00020). BG-V was funded by Junta de Castilla y
León and Fondo Social Europeo. Research grant provided by
Daiichi Sankyo to NORDICTUS. Investigators participating
in this study belong to the RETICS INVICTUS PLUS
financed by the Instituto de Salud Carlos III (RD1670019/0004,
RD16/0019/0018, RD16/0019/0019, and RD16/0019/0020).
Frontiers in Neurology | www.frontiersin.org 6 November 2020 | Volume 11 | Article 594251
Ramos-Araque et al. Anticoagulation, Bleeding and Mechanical Thrombectomy
ACKNOWLEDGMENTS
List of all NORDICTUS investigators is available at the
Supplementary Annex. Thanks to Dr. Javaad Ahmad for the
revision of English grammar.
SUPPLEMENTARY MATERIAL




1. Meinel TR, Kniepert JU, Seiffge DJ, Gralla J, Jung S, Auer E, et al. Endovascular
stroke treatment and risk of intracranial hemorrhage in anticoagulated
patients. Stroke. (2020) 51:892–8. doi: 10.1161/STROKEAHA.119.026606
2. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC,
Becker K, et al. Guidelines for the early management of patients with acute
ischemic stroke: 2019 update to the 2018 guidelines for the early management
of acute ischemic stroke a guideline for healthcare professionals from the
American Heart Association/American Stroke A. Stroke. (2019) 50:344–
418. doi: 10.1161/STR.0000000000000211
3. L’allinec V, Ernest M, Sevin-Allouet M, Testard N, Delasalle-Guyomarch
B, Guillon B, et al. Safety and efficacy of mechanical thrombectomy in
acute ischemic stroke of anticoagulated patients. J Neurointerv Surg. (2018)
10:E29. doi: 10.1136/neurintsurg-2017-013714
4. Vidale S, Agostoni E. Endovascular treatment of ischemic stroke: an updated
meta-analysis of efficacy and safety. Vasc Endovascular Surg. (2017) 51:215–
9. doi: 10.1177/1538574417698905
5. Wong JWP, Churilov L, Dowling R, Mitchell P, Bush S, Kanesan L, et al. Safety
of endovascular thrombectomy for acute ischaemic stroke in anticoagulated
patients ineligible for intravenous thrombolysis. Cerebrovasc Dis. (2019)
46:193–9. doi: 10.1159/000493801
6. Goldhoorn R-JB, van de Graaf RA, van Rees JM, Lingsma HF, Dippel
DWJ, Hinsenveld WH, et al. Endovascular treatment for acute
ischemic stroke in patients on oral anticoagulants. Stroke. (2020)
51:1781–9. doi: 10.1161/STROKEAHA.119.028675
7. Mundiyanapurath S, Tillmann A, Möhlenbruch MA, Bendszus M,
Ringleb PA. Endovascular stroke therapy may be safe in patients with
elevated international normalized ratio. J Neurointerv Surg. (2017)
9:1187–90. doi: 10.1136/neurintsurg-2016-012757
8. Pandhi A, Tsivgoulis G, Ishfaq MF, Katsanos A, Magoufis G, Malhotra
K, et al. Mechanical thrombectomy outcomes in large vessel stroke
with high international normalized ratio. J Neurol Sci. (2019) 396:193–
8. doi: 10.1016/j.jns.2018.11.019
9. Diener HC, Foerch C, Riess H, Röther J, Schroth G, Weber R.
Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in
patients receiving anti-thrombotic treatment. Lancet Neurol. (2013) 12:677–
88. doi: 10.1016/S1474-4422(13)70101-7
10. Pexman JH, Barber PA, Hill MD, Sevick RJ, Demchuk AM, Hudon ME,
et al. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for
assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol.
(2001) 22:1534–42.
11. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S,
et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion
imaging. N Engl J Med. (2018) 378:708–18. doi: 10.1056/NEJMoa1713973
12. Chung JW, Park SH, KimN, KimWJ, Park JH, Ko Y, et al. Trial of ORG 10172
in acute stroke treatment (TOAST) classification and vascular territory of
ischemic stroke lesions diagnosed by diffusion-weighted imaging. J Am Heart
Assoc. (2014) 3:1–8. doi: 10.1161/JAHA.114.001119
13. Zaidat OO, Yoo AJ, Khatri P, Tomsick TA, Von Kummer R, Saver
JL, et al. Recommendations on angiographic revascularization grading
standards for acute ischemic stroke: a consensus statement and for the
cerebral angiographic revascularization, grading (CARG) Collaborators,
STIR Revascularization working group, and STIR Thrombol. Stroke. (2013)
44:2630–63. doi: 10.1161/STROKEAHA.113.001972
14. Hacke W, Kaste M, Fieschi C, Von Kummer R, Davalos A, Meier D, et al.
Randomised double-blind placebo-controlled trial of thrombolytic therapy
with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet.
(1998) 352:1245–51. doi: 10.1016/S0140-6736(98)08020-9
15. Von Kummer R, Broderick JP, Campbell BCV, Demchuk A, Goyal M, Hill
MD, et al. The heidelberg bleeding classification: classification of bleeding
events after ischemic stroke and reperfusion therapy. Stroke. (2015) 46:2981–
6. doi: 10.1161/STROKEAHA.115.010049
16. Rebello LC, Haussen DC, Belagaje S, Anderson A, Frankel
M, Nogueira RG. Endovascular treatment for acute ischemic
stroke in the setting of anticoagulation. Stroke. (2015) 46:3536–
9. doi: 10.1161/STROKEAHA.115.011285
17. Liu M, Zheng Y, Li G. Safety of recanalization therapy in patients
with acute ischemic stroke under anticoagulation: a systematic
review and meta-analysis. J Stroke Cerebrovasc Dis. (2018)
27:2296–305. doi: 10.1016/j.jstrokecerebrovasdis.2018.04.012
18. Uphaus T, Singer OC, Berkefeld J, Nolte CH, Bohner G, Niederkorn K,
et al. Safety of endovascular treatment in acute stroke patients taking oral
anticoagulants. Int J Stroke. (2017) 12:412–5. doi: 10.1177/17474930166
77986
19. L’Allinec V, Sibon I, Mazighi M, Labreuche J, Kyheng M,
Boissier E, et al. MT in anticoagulated patients: direct oral
anticoagulants versus vitamin K antagonists. Neurology. (2020)
94:e842–50. doi: 10.1212/WNL.0000000000008873
20. Benavente L, Larrosa D, García-Cabo C, Pérez ÁI, Rico M, Vega P,
et al. Safety and efficacy of mechanical thrombectomy in acute ischemic
stroke of anticoagulated patients-a prospective observational study. J Stroke
Cerebrovasc Dis. (2016) 25:2093–8. doi: 10.1016/j.jstrokecerebrovasdis.2016.
06.006
21. Boeckh-Behrens T, SchubertM, Förschler A, Prothmann S, Kreiser K, Zimmer
C, et al. The impact of histological clot composition in embolic stroke. Clin
Neuroradiol. (2016) 26:189–97. doi: 10.1007/s00062-014-0347-x
22. Zapata-Wainberg G, Ximénez-Carrillo Á, Trillo S, Fuentes B, Cruz-Culebras
A, Aguirre C, et al. Mechanical thrombectomy in orally anticoagulated
patients with acute ischemic stroke. J Neurointerv Surg. (2018) 10:834–
8. doi: 10.1136/neurintsurg-2017-013504
Conflict of Interest: JA reports having received speaker or consultant honoraria
by: BI, Bayer, Daiichy Sankyo, Pfizer, Amgen, Medtronic. MC has received speaker
honoraria from Pfizer-BristolMyers Squibb, Daichii-Sankyo, and Boehringer-
Ingelheim, and for providing consultancy on advisory board meetings from
Amgen and Allergan.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Ramos-Araque, Chavarría-Miranda, Gómez-Vicente,
López-Cancio Martínez, Castañón Apilánez, Castellanos, López Fernández,
Tejada Meza, Marta Moreno, Tejada García, Beltrán Rodríguez, de la Riva, Díez,
Arias Rivas, Santamaría Cadavid, Bravo Anguiano, Bártulos Iglesias, Palacio
Portilla, Revilla García, Timiraos Fernández, Arenaza Basterrechea, Maciñeiras
Montero, Vicente Alba, Julián Villaverde, Pinedo Brochado, Azkune, Mar, Luna and
Arenillas. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction
in other forums is permitted, provided the original author(s) and the copyright
owner(s) are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Neurology | www.frontiersin.org 7 November 2020 | Volume 11 | Article 594251
